Hepatocellular carcinoma is the second leading cause of cancer deaths worldwide. It is characterized by unique features that can be utilized for selective and targeted therapy, which aids in preserving healthy tissues from deteriorating effects of traditional chemotherapeutics. In this minireview, a brief overview of recent drug delivery attempts for the management of hepatocellular carcinoma with the aid of nanomedical structures is presented. The beneficial impact of nanomaterials in terms of prolonged retention in blood and target sites, controlled biodistribution and improved stability of the encapsulated payloads, will be described, together with the possibility of incorporating more than one cargo into the same nanostructure. Incorporation of stimuli-responsive components, decoration with targeting moieties and the use of molecularly targeted drugs for treatment of hepatocellular carcinoma are also highlighted.
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HCC Is Unique in Nature
HCC is a primary malignancy of the liver and the most frequent type of liver cancer that accounts for 85% of primary liver cancers. Liver cancer is considered as the second leading cause of cancer deaths with nearly 746,000 deaths globally in 2012.
1 HCC arises on a background of chronic liver disease and cirrhosis and may have various etiologies, mainly viral hepatitis. HCC emerges as a result of genetic and epigenetic alterations, which consequently cause molecular alterations (e.g., upregulation of surface receptors responsible for growth and angiogenesis). Hence, HCC acquires some characteristics, such as, invasion, metastasis, insensitivity to antigrowth signals and self-sufficiency in growth factors, due to genetic alterations, including, genetic mutation, overexpression of specific oncogenes, amplifications, deletions and epigenetic deactivation of specific tumor suppressor genes. 2 The expression of several upstream and downstream effectors changes due to these genetic and epigenetic alterations, consequently creating a complex environment that uniquely defines HCC. Most HCC cases are developed on a background of prolonged inflammatory processes (i.e., chronic hepatitis and cirrhosis), mainly, as complications of HBV and HCV viral infections. 3 Other risk factors include age, gender and cirrho-the host genome and produces HBx protein that is involved in HCC carcinogenesis. 6 As early as in the preneoplastic stage, HBx acts as a tumor promoter and participates in several mechanisms that have been linked to cellular proliferation. For example, it binds to tumor suppressor protein p53 (which is a cell proliferation regulator) and thus, hindering the control of cellular proliferation. 7 Hence, targeting HBx can be effective in HCC therapy, particularly at the preneoplastic stage.
The expression of tumor suppressor genes, p53 and retinoblastoma, are frequently altered in HCC. [8] [9] [10] Alterations in p53 expression are frequent in more advanced stages of the disease. 11 Signal transduction usually occurs via binding of ligands to their receptors located on cell surfaces, which produces signals that are transferred through signaling pathways through the cell and to the nucleus. In HCC, such pathways are frequently altered, including the receptor-activated tyrosine kinase pathway, an important and commonly observed signaling pathway that contributes to carcinogenesis. It comprises RAS/RAF/MEK/ERK, PI3K/Akt/mTOR and NF-k B.
12-15 RAF is a kinase protein that is involved in cellular proliferation, angiogenesis and apoptosis of normal cells via signal transduction through RAF, MEK and ERK pathways, and it is usually overstimulated in HCC. Therefore, targeting RAF slows down the disease progression. Another important pathway in HCC carcinogenesis is the wnt/b-catenin signaling pathway as it is the second most frequently altered (mutated) pathway in HCC, secondary to the p53 gene. 16, 17 It is suggested that the highly resistant nature of HCC is mainly due to these genetic mutations in tumor suppressor genes (in particular p53 gene), thus making HCC nonresponsive to conventional antineoplastics. 18 Since HCC are highly vascular tissues, angiogenesis is a crucial process to tumor progression. VEGF is highly expressed in HCC. VEGF is a key effector in stimulating angiogenesis and in enhancing vascular permeability. 19 Similarly, PDGFR-b is also involved in angiogenesis. Side by side, bFGF, IGF, angiopoietin-1 and IL-8, are all involved in the neovascularization of tumors, including HCC. 20 EGFR, which are involved in cellular proliferation and differentiation, are also frequently overexpressed on HCC surface membranes and are usually correlated with poor prognosis. 21 These molecular alterations are heterogenic and differ according to HCC stage and etiology. In HCC, several molecules are expressed more often (e.g., VEGFR, RAF and EGFR), which could be extremely useful targets in the development of selective therapeutics. In addition, the unique expression of surface molecules in liver cells, such as, ASGP-R, endocytic cell surface receptors, which are highly expressed by hepatocytes 22 and by HCC cells, 23 and are not expressed by other tissues, can be exploited for targeted drug delivery. 24 Similarly, GA receptors are highly expressed on the surfaces of hepatocytes, and they are frequently exploited for selective delivery to the liver. 25 Altered molecules in HCC, either proteins expressed on the membrane surface or secreted by cells, or enzymes upregulated endogenously, can be utilized as targets for drug delivery to increase uptake, accumulation and activation of drugs inside the tumor cells. In addition, the specific genotypic and phenotypic alterations can also be utilized for targeted therapy and diagnosis.
Current Treatment Strategies
HCC is usually diagnosed at an advanced stage of the disease, especially in developing countries where screening processes are insufficient. According to the BCLC staging system, earlydiagnosed HCC of lesion size < 2 cm, normal bilirubin levels and normal portal pressure, can be treated surgically by resection, with excellent long-term survival. As early as stage A, where there is a single tumor < 5 cm or multiple tumors 3 cm and portal hypertension, liver transplantation is performed, if the liver functions are compensated. If liver functions are decompensated, or in the presence of associated diseases, techniques, such as, percutaneous ethanol injection or RFA, are routinely performed to reduce the tumor lesion size. In intermediate stage (stage B), locoregional therapy, such as transarterial chemoembolization, is utilized by taking advantage of the preferential blood supply of the hepatic artery to the tumor, thus localizing the cytotoxic effect to the tumor and preserving healthy tissues. In this technique, a catheter is inserted through the hepatic artery and a chemotherapeutic agent, such as, doxorubicin, cisplatin, or mitomycin C, are administered via the tumor feeding arteries. At an advanced stage of the disease, systemic chemotherapy becomes necessary if the liver functions are compensated. Surgical intervention is not possible for patients diagnosed at advanced stages, patients with poor liver functions, or patients who have other contraindications, such as, portal hypertension/hyperbilirubinemia, with associated diseases and, thus, limiting the number of patients eligible for surgery. Systemic conventional chemotherapy has several limitations, such as poor therapeutic outcomes and significant side effects, which are due to the lack of target selectivity and the high risk of recurrence and MDR to anti-neoplastic agents. In HCC, MDR is closely related to the overexpression of ABC transporter proteins, which lower the intracellular accumulation of drugs by pumping them out of the cell membrane. MDR1, BCRP, MRP1 and LRP have to date been the most important proteins contributing to the MDR of malignant cells. 26 Targeting HCC-specific molecules via molecularly targeted drugs may have a great potential in the management of HCC as compared to the conventional chemotherapeutics. In addition, encapsulation of anticancer drugs into nanomaterials allows for greater accumulation of chemotherapeutics in the tumor tissues. Moreover, these nanomaterials can be selectively delivered to the tumor sites via specific recognition of some molecules overexpressed by tumor tissues, and can also be equipped with diagnostic agents (fluorescent probes, metallic nanoparticles, radiolabels, etc.) for theranostic (therapy and diagnosis) applications.
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Molecular Therapy
Several molecularly targeted drugs are being developed and investigated to provide high therapeutic efficacy and safety profile for HCC patients. The use of some of these drugs in the treatment of HCC is briefly discussed in this minireview ( Fig. 1) . Sorafenib is the first and the only FDA-approved molecularly targeted drug for systemic treatment of advanced HCC. 31, 32 It targets molecules present in tumor cells and in cells of the tumor vessels. It inhibits angiogenesis and cellular proliferation by binding to the surface receptors, VEGFR 2, VEGFR 3, PDGFR b and the downstream signaling pathway RAF, MEK, ERK. Bevacizumab is a recombinant humanized monoclonal antibody directed against VEGFR. It has been tested alone and in combination with other agents. Brivanib is a multi-TKI that inhibits both fibroblast growth factor receptor and VEGFR. Sunitinib is another multi-TKI that blocks various receptors, such as, VEGFR 1, VEGFR 2, PDGFR-a, PDGFR-b and it has demonstrated moderate results in a phase II clinical trial with median free survival of 3.9 months and OS of 9.8 months. 33 In another phase II study, it was discontinued because study endpoints were not met (one patient of the 36 showed confirmed partial response rate, giving an overall response rate of 2.7%). Moreover, the study results reflected that sunitinib caused pronounced toxicities at a dose of 50 mg/day. 34 In a phase III clinical trial, when compared to sorafenib, OS of sunitinib was inferior to OS of sorafenib (7.9 vs. 10.2 months, respectively). 35 However, promising results were found in a multicenter phase II clinical trial when sunitinib was given to advanced HCC patients with median TTP of 1.5 months and an increase in OS to 9.3 months. 36 Everolimus is also a TKI that targets mTOR. Despite the anti-tumoral effects that were demonstrated in preclinical models, no improvement in OS was achieved when compared to a placebo group of advanced HCC patients after failure of sorafenib. 37 Also, when studied in combination with sorafenib, the MTD failed to achieve biologically-effective concentration (OS 5 7.4 months, TTP 5 4.5 months), and thus the phase II clinical trial was terminated. 38 Although there are several drugs have been extensively investigated for treatment of HCC, none so far has revealed superior or equivalent therapeutic outcomes when compared with sorafenib.
There have been also several attempts for management of HCC through the use of nucleic acids-based drugs, which are widely utilized for treatment of cancer, and other diseases. For example, siRNA is a double stranded RNA of [19] [20] [21] [22] basepairs that functions by binding to RNA-induced silencing complexes, where the sense strand is removed. Then, the silencing complexes with the antisense strands specifically cleaves target mRNA, thus, inhibiting gene expression posttranscriptionally. 39 In addition, short miRs are small (ca. 22 nucleotides) noncoding RNAs that regulate gene expression Figure 1 . Demonstration of different molecular targets and pathways that are targeted by commonly used drugs in the treatment of HCC. Molecular therapy includes tyrosine kinase inhibitors, such as sorafenib, which targets important upstream and downstream targets, including RAS, VEGFR and PDGFR. Sunitinib and brivanib both target VEGF, in addition to erlotinib, which targets EGF receptors. Molecular therapy also includes monoclonal antibodies, such as, bevacizumab, which targets VEGF. Doxorubicin is a topoisomerase II inhibitor that causes cell death. Gene therapy is also commonly utilized via exploiting nucleic acids, such as, plasmid DNA, siRNA, miRNA, etc., for insertion of genes or alteration of gene expression, to slow down tumor progression. [Color figure can be viewed at wileyonlinelibrary.com] post-transcriptionally by binding to partially complementary sites in the target mRNA. Types and mechanisms of actions of nucleic acids are beyond the scope of this review and have been reviewed elsewhere. 39 Despite their great potential to selectively withhold disease progression, therapeutic benefits of nucleic acids are limited by their low stability, rapid degradation by both extra-cellular and intra-cellular nucleases, insufficient cellular uptake, endosomal/lysosomal degradation and insufficient nuclear translocation. Furthermore, inflammatory cytokines can be induced after administration of nucleic acid-based drugs, which may initiate harmful inflammatory reactions. [39] [40] [41] Although the high efficiency of several chemotherapeutics and nucleic acid molecules in the management of cancer, the drugs are not usually delivered at high concentrations into the malignant tissues. Development of delivery vehicles loaded with anticancer drugs and/or nucleic acids and controlling the navigation of these carriers within the biological system via modifying their surface chemistries, can selectively concentrate these drugs into the tumor tissues and improve therapeutic outcomes with significant reduction of adverse reactions associated with the traditional chemotherapy.
Nanomedicine in the Management of Hepatocellular Carcinoma
Nanomedicine can be defined as the intentional design of therapeutics and diagnostics with control over their sizes and shapes in the nanoscale range (1-100 nm) for treatment, diagnosis and prevention of diseases. NPs are capable of serving as nanoscale drug delivery vehicles that act as a reservoir for drug entrapment, either physically and/or chemically. The surfaces of nanoparticles can also be decorated with various moieties for targeting and/or imaging applications. There are several types of nanomaterials, such as, liposomes, dendrimers, quantum dots, micelles, metallic NPs, nanoshells and carbon nanotubes. 42 Controlling the chemistries of the building blocks of nanoparticles and optimizing their compositions can control their permeability through various biological barriers, protect their cargoes from degradation and opsonization and enhance their cellular uptake and can be applied for various applications. [43] [44] [45] [46] Delivery of antineoplastic agents by nanocarriers may enhance selective accumulation into tumor tissues and decrease multidrug resistance. Accumulation of drug-loaded NPs into tumor tissues has been demonstrated via both passive and active targeting mechanisms. Passive targeting usually occurs via the EPR effect, whereas active targeting is achieved by modifying the surface of nanoparticles with targeting ligands and/or by inclusion of stimuli-(e.g., pH, temperature, ultrasound, etc.) responsive ingredients into one or more of the components of the nanostructures. Both passive and active targeting can modify the biodistribution of the encapsulated drug and possibly increase accumulation of drugs into the targeted tissues and decrease their levels into healthy tissues.
Encapsulation of various chemotherapeutics and/or nucleic acids into nanostructures of various compositions has improved the treatment of several diseases, and is considered as a potential tool for the treatment of HCC. Due to the complexity and high vascular nature of HCC and various molecular events involved, nanomedical devices might provide higher efficacy in the management of HCC, as compared with conventional therapeutics. Encapsulation of chemotherapeutics into nanoparticles and redirection of the biodistribution of the entrapped drug is expected to overcome the main challenges towards effective therapeutic strategies in HCC and reduce the systemic adverse effects that limit the cytotoxic dose administered (Fig. 2) . However, biocompatibility, toxicity, immunogenicity, degradability and stability all have to be carefully considered for the design of efficient nanocarriers. 47 
Targeting
Targeting can be achieved by designing nanovechiles that are conjugated to ligands that have high affinity to specific receptors solely expressed or overexpressed onto cancer cells. Hence, higher accumulation at the target sites and greater cellular internalization can be achieved, depending on the extent of receptor-ligand interaction, concentration of ligand on the surface of NPs, and the extent to which these receptors are expressed by cells (Table 1) . These targeting ligands can be utilized to modify surface of different types of nanoparticles, such as, polymeric, lipid-based and metallic nanoparticles, and these nanomaterials can also be loaded with several anticancer drugs. 29, [52] [53] [54] [55] Targeting ligands could be sugar residues, monoclonal antibodies, nucleic acid aptamers, proteins or other molecules with specific affinity to the target sites. 56 In particular, for HCC, galactose residues were frequently used to decorate the surfaces of NPs for selective hepatic delivery, due to their binding affinity to ASGP-R. [57] [58] [59] Targeting ASGP receptors showed an increase in organ selectivity for the targeted NPs. For example, 5-fluorouracil-loaded galactosylated chitosan NPs resulted in extensive accumulation of the drug at tumor tissues, as compared with other healthy tissues, with 8.69-, 23.35-, 79.96-and 85.15-fold increase in accumulation when compared to normal liver tissue, kidney, heart and blood, respectively. Furthermore, greater tumor inhibition was demonstrated when these NPs were tested on orthotropic mice models against the free drug, suggesting capability of targeted NPs to improve therapeutic efficacy by improving biodistribution profile of the encapsulated drug. 60, 61 ATP can bind to P2 receptors, a type of purinergic receptor that is expressed on cancer cells. ATP was used as a targeting ligand for selective delivery to HCC to promote cellular permeabilization. When it was conjugated onto NPs to deliver selenium (an essential trace element that has anticancer activity), an increase in cellular uptake of 3.5 times greater than the nontargeted NPs was observed, as indicated by the florescence generated by ATP targeted-6-coumarin-loaded selenium NPs, implying enhanced internalization of the drug into the target cells via receptor-mediated endocytosis. 62 Cyclic RGD is a peptide that binds to integrin protein receptors, which are frequently expressed on the liver surface and also in integrin-rich tumors. 63 This peptide was previously utilized as a targeting ligand for the delivery of NPs to melanoma cells, and also for several other tumor types. 64, 65 Interestingly, when RGD was used to decorate the surface of NPs and tested on hepatoma cells, an enhanced cellular uptake of up to 500-fold higher than the nontargeted NPs was observed, as indicated by the mean fluorescence intensity measured. Additionally, the specificity of cellular uptake was evaluated by incubating hepatoma cells with excess free RGD, which inhibited cellular uptake of the RGD-targeted NPs. Moreover, the RGD-modified NPs were taken up at lower levels by other cell lines of different origins (colon HT29 and cervical HeLa cancer cells). Hence, cyclic RGD might be used as targeting moieties for specific delivery of drugs to HCC cells. 66 GA and GL have specific binding sites on hepatocytes, and thus, can be used to decorate NPs for selective delivery to the liver. 67 GL-modified N-caproyl chitosan NPs displayed 2.1-fold greater uptake by hepatocytes than the non-targeted NPs. 68 Likewise, O-carboxymethyl chitosan NPs modified with GL at various substitution degrees were prepared and were assessed in two different cell lines, human liver cancer cell line (SMMC-7721) and human normal liver cell line (LO2). GL-modified NPs accumulated preferentially in SMMC-7721 cells and cellular uptake was 2.5-times greater than the uptake in LO2 cell line. GL-decorated NPs were taken up by SMMC-7721 cells 10-fold higher than the nondecorated NPs, suggesting an enhanced cellular binding and internalization. Moreover, GL-modified NPs afforded significantly superior residence time of the loaded drug in blood, preferential accumulation in liver and tumor tissues and eventually suppressed tumor growth to a greater extent than both the nontargeted-NPs and the free drug (inhibition rate of 88, 64 and 34.5%, for GL-targeted NPs, nontargeted NPs and the free drug, respectively). 69 Anthracyclines, especially doxorubicin, are frequently used for treatment of various types of tumors. The dose administered to patients is limited by the dose-dependent and cumulative cardiotoxicity. 70 In an attempt to eliminate its toxicity, doxorubicin was loaded into GA-modified alginate NPs and administered to mice. The concentration of doxorubicin in the liver was 2.8-fold and 4.7-fold higher than the nonmodified NPs and the free doxorubicin, respectively. Furthermore, relatively higher tumor growth inhibition rate of 76.6% was observed in mice bearing liver tumor with no mortality, as compared to 52.6% inhibition rate and 33% mortality rate in the free doxorubicin group. Unlike the free doxorubicin group, no adverse events either in heart or in healthy liver tissues were observed with the group of GA-targeted NPs. 71 LF is a non-haem iron-binding protein, which is a part of the transferrin protein family. 72 LF can be used to target HCC where it can bind to multiple receptors on hepatocytes prior to internalization, including low-density lipoprotein receptor-related protein and ASGP-R. 12 LF demonstrated high affinity to ASGP-R which are highly expressed on hepatocytes and hepatoma cells (vide supra). 73 In addition to its anticancer activity, LF was previously used to successfully decorate liposomes to deliver cargos to hepatoma cells to increase cellular binding and internalization in HCC cell line. Accumulation of drug into the tumors of HCC-bearing mice was superior to the drug loaded into the nontargeted NPs, as detected by fluorescence imaging. 74 mAbs, such as, anti-EGFR mAb, were frequently used to target HCC as they hold greater specificity than other targeting ligands, but, also greater immunogenicity. EGFR are upregulated on HCC cell surface membranes (vide supra). mAbs specific to EFGR were conjugated onto nanocomplexes encapsulating a plasmid DNA. These nanocomplexes produced greater transfection efficiency of the encapsulated gene as compared to the non-conjugated ones. In addition, higher accumulation into tumor tissues in vivo was observed with significant gene silencing, implying effective targeting ability of the anti-EGFR mAb.
75,76 SM5-1-targeted gold NPs have been also utilized for treatment and diagnosis of HCC. SM5-1 is a mAb that can target overexpressed membrane proteins onto HCC cells, in addition to inducing apoptosis and cell growth inhibition. In orthotopic HCC tumor models, nanoparticles resulted in about 39.64% inhibition rate on Day 31 post-treatment. 53 There are several types of NPs that have been utilized for codelivery of chemotherapeutics. [77] [78] [79] An example that highlights the higher efficiency of combinational therapy included the design of transferrin-targeted NPs loaded with doxorubicin and cisplatin. Compared with the non-targeted NPs and NPs loaded with a single drug, the NPs resulted in higher cytotoxicity and antitumor activity both in vitro and in vivo. 78 Other types of NPs (e.g., lipid/polymer hybrid) have been decorated with targeting ligands (e.g., iRGD peptide) and used for codelivery of doxorubicin and sorafenib, and demonstrated high antitumor efficiency in HCC xenograft mouse models.
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A recent and interesting approach for utilizing the interesting features of nanomaterials in assisted therapy and diagnosis of HCC has been investigated. 80 The authors utilized low-density lipoprotein for targeted delivery of the docosahexaenoic acid omega-3 fatty acid to the liver cells and demonstrated 3-fold regression in experimental tumor mass with preserving the healthy hepatic tissues. The effect was explained by affecting the redox balance of the HCC cells, which induces necrosis in the HCC tissues. Interestingly, they have injected the NPs directly into the hepatic artery, which minimize systemic exposure and enhance tumoral accumulation, and when the NPs were fluorescently tagged, they could assist in the imaging and resection of the tumors.
Stimuli-responsive nanocarriers
Targeting can also be achieved by remotely controlling the navigation and dynamics of NPs inside the body using internal (e.g., pH, tissue microenvironment, etc.) or external (e.g., magnetic field, ultrasound, radiofrequency ablation, microwaves, etc.) stimuli to allow for the preferential release of the loaded cargoes into the targeted tissues upon exposure to a stimulus (Table 1) . Tumor microenvironment is slightly acidic due to the high metabolic rate of tumor cells. A pHsensitive NPs encapsulating combretastatin A4 and methotrexate (MTX), and conjugated to pullulan, a pH-sensitive ligand for ASGP-R, were designed to treat HCC. 81, 82 NPs exhibited high affinity to HepG2 cells and have demonstrated an enhanced drug release at acidic pH in vitro. In vivo, prolonged circulation time, sustained drug release and controlled biodistribution were indicated by higher accumulation into the liver as compared with other tissues. 83 Several thermosensitive liposomal formulations were fabricated for the treatment of HCC, with the aid of external heating devices, such as, radiofrequency ablation, which is usually used for tumor down staging in HCC. 84 These liposomes release higher amounts of the loaded drug when exposed to heat, as compared with the conventional liposomal preparations. 84, 85 An example of temperature-sensitive carriers is ThermodoxV R , a dipalmitoylphosphatidylcholinebased liposomes. 86, 87 Changes in the structure of the liposomes upon heating (ca. 40-458C) form openings in the lipid bilayers, which allows the release of the loaded drug (i.e., doxorubicin). Subgroup analysis of data from 285 HCC patients of HEAT (HCC Study of RFA and ThermodoxV R ) study, which is a double blinded, placebo-controlled phase III clinical trial showed a 57% improvement in post-hoc OS in a combined therapy of ThermodoxV R and RFA. ThermodoxV R is currently being investigated in OPTIMA study, a phase III clinical trial, in combination with RFA in HCC patients.
Nucleic acids delivery attempts
Several attempts were conducted to investigate the beneficial effects of nanomedical structures in gene delivery to sensitize cancer cells to chemotherapy. A combined therapy of chitosan-based NP for delivery of doxorubicin and DNA coding for p53 gene was found to significantly decrease IC 50 from ca. 4.5 mg/mL for doxorubicin to about 1.6 mg/mL for the combined treatment (i.e., lowered by 3-fold). 88 EGFRtargeted PEGylated immunoliposomes were fabricated for delivery of siRNA and have demonstrated a relatively enhanced cellular uptake in vitro. 75 The liposomes provided higher tumor accumulation, greater tumor tissue necrosis and fewer blood vessel formation relative to the naked siRNA. 89 In addition, it was reported that miR-122 sensitizes HCC cells to sorafenib and doxorubicin. 90, 91 miR-34a is another microRNA that targets Bcl-2 and sensitizes HCC cells to sorafenib. 92 A cationic lipid NP formulation was used to deliver miR-122 and the median tumor weight of miR-122 group was 50% smaller (p 5 0.03) than the negative control group. 93 Anti-miR-155 (miR-155 is a hepatic oncogenic miR and its expression is correlated with some types of HCC)-loaded NPs were formulated using N-lactobionyl-dioleoylphosphatidylethanolamine (Lac-DOPE), a lipid conjugate, for preferential delivery to hepatocytes. In vitro and in vivo evaluations have demonstrated significant upregulations of antimiR-155 target genes, C/EBPb and FOXP3, by 6.9-fold and 2.2-fold, respectively, as compared with Lipofectamine 2000. 94 Polymeric PEGylated redox-responsive NPs have been complexed with tumor suppressor miR-34a and decorated with a targeting oligopeptide SP94. The NPs had higher affinity to HCC cells than hepatocytes in vitro and displayed greater inhibition of tumor growth in vivo. 95 Further investigations are recommended to evaluate the ability of nucleic acids to improve therapeutic outcomes of the current strategies available for the treatment of HCC.
Nanomaterials with endogenous cytotoxicity
Interestingly, some polymeric materials incorporated into NP preparations have demonstrated endogenous cytotoxic properties, and thus, they can be exploited to synergistically enhance the cytotoxic effect of anticancer drugs. These polymers include chitosan which displayed endogenous dose-and size-dependent anti-tumor properties via inducing cell necrosis. Upon exposure of cells to positively charged chitosan NPs for 72 hr, tumor cell necrosis and cell viability reduction were observed. In addition, decreased negative charge and potential of mitochondrial membrane, lipid peroxidation and alteration in cell membrane were found. Noteworthy, an increase in the surface charge of the NPs, as well as, a decrease in particle size led to greater interaction with the negatively charged membranes and, accordingly, enhanced accumulation, cellular uptake and anti-tumoral effect. 96, 97 This effect is attributed to membrane disruption and induced apoptosis. 97 Similarly, the targeting ligand Lf exhibited anticancer effects in multiple tumors, such as, colorectal cancer, lung cancer, intestinal polyposis and stomach cancer.
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When investigated in vitro in HCC, it acted as a tissue proliferation and differentiation regulator. 101 Pluronics have shown to chemosensitize cancer cells via inhibiting P-glycoprotein, an ATP-dependent efflux pump that expels drug molecules out of cancer cells, multidrug resistant protein and BCRPmediated resistance, which have considerable contribution to the resistance of HCC to chemotherapy.
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Conclusions
HCC is a complex disease in nature with a progressive rate of incidence and mortality. Treatment of HCC with the aid of nanomedical structures is greatly encouraged as it utilizes attractive features provided by the EPR effect, together with controlled biodistribution and release of the loaded drugs into the target sites. NPs can also be loaded with nucleic acids and with more than one drug to overcome MDR. Entire parameters contributing to the overall stability, efficacy, biodistribution and industrial scalability should be carefully assessed and evaluated to maximize the therapeutic outcomes, to improve patient compliance, and to provide new therapeutics for the management of HCC.
